9,733 Shares in ClearPoint Neuro, Inc. (NASDAQ:CLPT) Bought by Ieq Capital LLC

Ieq Capital LLC bought a new position in ClearPoint Neuro, Inc. (NASDAQ:CLPT) during the first quarter, according to the company in its most recent filing with the SEC. The firm bought 9,733 shares of the company’s stock, valued at approximately $206,000.

A number of other large investors have also modified their holdings of the stock. Dorsey Wright & Associates raised its position in ClearPoint Neuro by 134.6% in the 1st quarter. Dorsey Wright & Associates now owns 3,069 shares of the company’s stock worth $65,000 after purchasing an additional 1,761 shares during the period. Taylor Frigon Capital Management LLC bought a new stake in ClearPoint Neuro in the 1st quarter worth $1,182,000. Clarus Group Inc. bought a new stake in ClearPoint Neuro in the 1st quarter worth $135,000. JPMorgan Chase & Co. grew its holdings in ClearPoint Neuro by 2,640.5% in the 4th quarter. JPMorgan Chase & Co. now owns 41,327 shares of the company’s stock worth $657,000 after acquiring an additional 39,819 shares during the last quarter. Finally, Parian Global Management LP bought a new stake in ClearPoint Neuro in the 4th quarter worth $7,359,000. Institutional investors own 6.61% of the company’s stock.

Shares of CLPT opened at $18.08 on Monday. The firm’s 50-day moving average price is $19.99 and its 200-day moving average price is $17.99. The firm has a market capitalization of $375.36 million, a price-to-earnings ratio of -41.09 and a beta of 1.15. The company has a current ratio of 5.42, a quick ratio of 4.47 and a debt-to-equity ratio of 118.51. ClearPoint Neuro, Inc. has a 1-year low of $3.02 and a 1-year high of $31.29.

ClearPoint Neuro (NASDAQ:CLPT) last announced its earnings results on Monday, May 10th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. ClearPoint Neuro had a negative net margin of 55.55% and a negative return on equity of 309.91%. On average, research analysts forecast that ClearPoint Neuro, Inc. will post -0.42 EPS for the current fiscal year.

A number of equities research analysts have issued reports on CLPT shares. Zacks Investment Research lowered shares of ClearPoint Neuro from a “buy” rating to a “hold” rating in a report on Wednesday, May 5th. Lake Street Capital started coverage on shares of ClearPoint Neuro in a report on Wednesday, March 24th. They issued a “buy” rating and a $32.00 price target on the stock. Finally, B. Riley reissued a “buy” rating and issued a $38.00 price target (up previously from $23.00) on shares of ClearPoint Neuro in a report on Monday, February 22nd.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies.

See Also: 12b-1 Fees

Institutional Ownership by Quarter for ClearPoint Neuro (NASDAQ:CLPT)

Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.